Yong Chan Kim - Jul 3, 2023 Form 3 Insider Report for Baudax Bio, Inc. (BXRX)

Role
Director
Signature
/s/ Jillian Dilmore, Attorney-in-fact
Stock symbol
BXRX
Transactions as of
Jul 3, 2023
Transactions value $
$0
Form type
3
Date filed
7/13/2023, 04:21 PM

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding BXRX Common Stock 202K Jul 3, 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding BXRX Series X Preferred Stock Jul 3, 2023 Common Stock 4.52M Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares of Series X Non-Voting Convertible Preferred Stock, par value $0.01 per share (the "Series X Preferred Stock"), shall automatically convert into the Issuer's common stock based on the Conversion Ratio and subject to certain limitations, including the Beneficial Ownership Limitation (as such terms are defined in the Certificate of Designations of Series X Non-Voting Convertible Preferred Stock filed with the Securities and Exchange Commission as Exhibit 3.1 to the Issuer's Form 8-K filed on July 5, 2023), effective as of 5:00 p.m. Eastern Time on the second trading day after the date on which the Issuer's stockholders approve the conversion of the Series X Preferred Stock.

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney